Patents by Inventor Garry Smith
Garry Smith has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240059649Abstract: Novel substituted N-acetyl-L-cysteine (NAC) derivatives and related compounds and methods of using these compounds for the treatment of diseases and/or conditions, including but not limited to diseases and/or conditions of, or involving, the Central Nervous System (CNS), including schizophrenia adrenoleukodystrophy, mitochondrial diseases (e.g. Leigh syndrome, Alpers' disease, and MELAS), Huntington's disease, trichotillomania, HIV-associated neurocognitive disorder, hypoxic-ischemic encephalopathy, drug craving, and drug addiction.Type: ApplicationFiled: October 17, 2023Publication date: February 22, 2024Applicant: Promentis Pharmaceuticals, Inc.Inventors: Michael Neary, James Nieman, Steven Tanis, Daniel Lawton, Garry Smith
-
Publication number: 20210395194Abstract: Novel substituted N-acetyl-L-cysteine (NAC) derivatives and related compounds and methods of using these compounds for the treatment of diseases and/or conditions, including but not limited to diseases and/or conditions of, or involving, the Central Nervous System (CNS), including schizophrenia adrenoleukodystrophy, mitochondrial diseases (e.g. Leigh syndrome, Alpers' disease, and MELAS), Huntington's disease, trichotillomania, HIV-associated neurocognitive disorder, hypoxic-ischemic encephalopathy, drug craving, and drug addiction.Type: ApplicationFiled: March 29, 2021Publication date: December 23, 2021Applicant: Promentis Pharmaceuticals, Inc.Inventors: Michael Neary, James Nieman, Steven Tanis, Daniel Lawton, Garry Smith
-
Patent number: 10961187Abstract: Novel substituted N-acetyl-L-cysteine (NAC) derivatives and related compounds and methods of using these compounds for the treatment of diseases and/or conditions, including but not limited to diseases and/or conditions of, or involving, the Central Nervous System (CNS), including schizophrenia adrenoleukodystrophy, mitochondrial diseases (e.g. Leigh syndrome, Alpers' disease, and MELAS), Huntington's disease, trichotillomania, HIV-associated neurocognitive disorder, hypoxic-ischemic encephalopathy, drug craving, and drug addiction.Type: GrantFiled: June 17, 2019Date of Patent: March 30, 2021Assignee: Promentis Pharmaceuticals, Inc.Inventors: Michael Neary, James Nieman, Steven Tanis, Daniel Lawton, Garry Smith
-
Publication number: 20190315683Abstract: Novel substituted N-acetyl-L-cysteine (NAC) derivatives and related compounds and methods of using these compounds for the treatment of diseases and/or conditions, including but not limited to diseases and/or conditions of, or involving, the Central Nervous System (CNS), including schizophrenia adrenoleukodystrophy, mitochondrial diseases (e.g. Leigh syndrome, Alpers' disease, and MELAS), Huntington's disease, trichotillomania, HIV-associated neurocognitive disorder, hypoxic-ischemic encephalopathy, drug craving, and drug addiction.Type: ApplicationFiled: June 17, 2019Publication date: October 17, 2019Applicant: Promentis Pharmaceuticals, Inc.Inventors: Michael Neary, James Nieman, Steven Tanis, Daniel Lawton, Garry Smith
-
Patent number: 10358414Abstract: Novel substituted N-acetyl-L-cysteine (NAC) derivatives and related compounds and methods of using these compounds for the treatment of diseases and/or conditions, including but not limited to diseases and/or conditions of, or involving, the Central Nervous System (CNS), including schizophrenia adrenoleukodystrophy, mitochondrial diseases (e.g. Leigh syndrome, Alpers? disease, and MELAS), Huntington's disease, trichotillomania, HIV-associated neurocognitive disorder, hypoxic-ischemic encephalopathy, drug craving, and drug addiction.Type: GrantFiled: April 7, 2017Date of Patent: July 23, 2019Assignee: Promentis Pharmaceuticals, Inc.Inventors: Michael Neary, James Nieman, Steven Tanis, Daniel Lawton, Garry Smith
-
Publication number: 20170210716Abstract: Novel substituted N-acetyl-L-cysteine (NAC) derivatives and related compounds and methods of using these compounds for the treatment of diseases and/or conditions, including but not limited to diseases and/or conditions of, or involving, the Central Nervous System (CNS), including schizophrenia adrenoleukodystrophy, mitochondrial diseases (e.g. Leigh syndrome, Alpers? disease, and MELAS), Huntington's disease, trichotillomania, HIV-associated neurocognitive disorder, hypoxic-ischemic encephalopathy, drug craving, and drug addiction.Type: ApplicationFiled: April 7, 2017Publication date: July 27, 2017Applicant: Promentis Pharmaceuticals, Inc.Inventors: Michael Neary, James Nieman, Steven Tanis, Daniel Lawton, Garry Smith
-
Patent number: 9630937Abstract: Novel substituted N-acetyl-L-cysteine (NAC) derivatives and related compounds and methods of using these compounds for the treatment of diseases and/or conditions, including but not limited to diseases and/or conditions of, or involving, the Central Nervous System (CNS), including schizophrenia adrenoleukodystrophy, mitochondrial diseases (e.g. Leigh syndrome, Alpers' disease, and MELAS), Huntington's disease, trichotillomania, HIV-associated neurocognitive disorder, hypoxic-ischemic encephalopathy, drug craving, and drug addiction.Type: GrantFiled: November 7, 2014Date of Patent: April 25, 2017Assignee: Promentis Pharmaceuticals, Inc.Inventors: Michael Neary, James Nieman, Steven Tanis, Daniel Lawton, Garry Smith
-
Publication number: 20150344419Abstract: The invention relates to compounds of the following formula: and their pharmaceutically acceptable salts, pharmaceutical compositions containing this compounds, and methods of using this compound for the treatment of various diseases or conditions, including but not limited to diseases and/or conditions of, or involving, the Central Nervous System (CNS), including schizophrenia adrenoleukodystrophy, mitochondrial diseases (e.g. Leigh syndrome, Alpers' disease, and MELAS), Huntington's disease, trichotillomania, HIV-associated neurocognitive disorder, hypoxic-ischemic encephalopathy, drug craving, and drug addiction.Type: ApplicationFiled: November 7, 2014Publication date: December 3, 2015Inventors: Michael Neary, Mark A. Wolf, Keith D. Barnes, Garry Smith
-
Patent number: 9193681Abstract: The invention relates to compounds of the following formula: and their pharmaceutically acceptable salts, pharmaceutical compositions containing this compounds, and methods of using this compound for the treatment of various diseases or conditions, including but not limited to diseases and/or conditions of, or involving, the Central Nervous System (CNS), including schizophrenia adrenoleukodystrophy, mitochondrial diseases (e.g. Leigh syndrome, Alpers' disease, and MELAS), Huntington's disease, trichotillomania, HIV-associated neurocognitive disorder, hypoxic-ischemic encephalopathy, drug craving, and drug addiction.Type: GrantFiled: November 7, 2014Date of Patent: November 24, 2015Assignee: Promentis Pharmaceuticals, Inc.Inventors: Michael Neary, Mark A. Wolf, Keith D. Barnes, Garry Smith
-
Publication number: 20150133470Abstract: Novel substituted N-acetyl-L-cysteine (NAC) derivatives and related compounds and methods of using these compounds for the treatment of diseases and/or conditions, including but not limited to diseases and/or conditions of, or involving, the Central Nervous System (CNS), including schizophrenia adrenoleukodystrophy, mitochondrial diseases (e.g. Leigh syndrome, Alpers' disease, and MELAS), Huntington's disease, trichotillomania, HIV-associated neurocognitive disorder, hypoxic-ischemic encephalopathy, drug craving, and drug addiction.Type: ApplicationFiled: November 7, 2014Publication date: May 14, 2015Inventors: Michael Neary, James Nieman, Steven Tanis, Daniel Lawton, Garry Smith
-
Patent number: 5294648Abstract: A binder composition for producing articles of bonded particulate material such as foundry molds or core comprises an alkaline aqueous solution of a resol phenol-aldehyde resin, an oxyanion which can form a stable complex with the resin, and an ethylene glycol monoalkyl ether. The binder composition has an alkali to phenol molar ratio of from 1.5:1 to 2.5:1 and the amount of alkali present in the solution is sufficient to substantially prevent stable complex formation between the resin ad the oxyanion. Bonded articles are produced by passing carbon dioxide gas through articles formed from a mixture of particulate material and the binder composition so as to produce stable complex formation and curing of the resin.Type: GrantFiled: January 4, 1993Date of Patent: March 15, 1994Assignee: Foseco International LimitedInventors: Garry Smith, Martin Bradley
-
Patent number: 5242957Abstract: A binder composition for producing articles of bonded particulate material such as foundry molds or cores comprises an alkaline aqueous solution of a resol phenol-aldehyde resin, an oxyanion which can form a stable complex with the resin, and a phenyl ethylene glycol ether. The binder composition has an alkali to phenol molar ratio of from 1.5:1 to 2.5:1 and the amount of alkali present in the solution is sufficient to substantially prevent stable complex formation between the resin and the oxyanion. Bonded articles are produced by passing carbon dioxide gas through articles formed from a mixture of particulate material and the binder composition so as to produce stable complex formation and curing of the resin.Type: GrantFiled: February 13, 1992Date of Patent: September 7, 1993Assignee: Foseco International LimitedInventors: Garry Smith, Martin Bradley
-
Patent number: 5198478Abstract: A binder composition for producing articles of bonded particulate material such as foundry moulds or cores comprises an alkaline aqueous solution of a resol phenol-aldehyde resin, an oxyanion which can form a stable complex with the resin, and pyrrolidone or an N-substituted pyrrolidone, and the amount of alkali present in the solution is sufficient to substantially prevent stable complex formation between the resin and the oxyanion. Bonded articles are produced by passing carbon dioxide gas through articles formed from a mixture of particulate material and the binder composition so as to produce stable complex formation and curing of the resin.Type: GrantFiled: February 11, 1992Date of Patent: March 30, 1993Assignee: Foseco International LimitedInventors: Garry Smith, Martin Bradley